eli lilly & co (LLY) Key Developments
Eli Lilly and Company Declares Second Quarter of 2015 Dividend, Payable on June 10, 2015
May 4 15
The board of directors of Eli Lilly and Company has declared a dividend for the second quarter of 2015 of $0.50 per share on outstanding common stock. The dividend is payable on June 10, 2015, to shareholders of record at the close of business on May 18, 2015.
Eli Lilly and Company Announces Positive Results from Phase Iii Psoriatic Arthritis Study
May 4 15
Eli Lilly and Company has announced results from a Phase III study which showed that its investigational medicine, ixekizumab, was statistically superior to placebo in the treatment of patients with active psoriatic arthritis, or PsA, as demonstrated by the proportion of patients achieving an ACR 20 response. ACR 20 is a standard assessment that represents a 20% reduction in disease signs and symptoms as defined by the American College of Rheumatology response criteria. During the 24-week, Phase III study, titled SPIRIT-P1, patients who were naive to biologic disease-modifying antirheumatic drugs (bDMARD) were treated with one of two different ixekizumab dosing regimens or placebo. In both dosing regimens, ixekizumab-treated patients demonstrated significant improvements versus placebo in signs and symptoms of active PsA.
Eli Lilly and Company Receives U.S. Food and Drug Administration Approval for CYRAMZA
Apr 24 15
Eli Lilly and Company has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. The approval is based on the Phase III trial known as RAISE, which compared CYRAMZA plus FOLFIRI to placebo plus FOLFIRI in people with mCRC who had disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Efficacy endpoints in the trial included the major efficacy outcome measure of overall survival (OS) and the supportive efficacy outcome measure of progression-free survival (PFS). The labeling for CYRAMZA contains Boxed Warnings for: hemorrhage, including severe and sometimes fatal events; gastrointestinal (GI) perforation, a potentially fatal event; and impaired wound healing. CYRAMZA should be permanently discontinued in patients who experience severe bleeding or a GI perforation. CYRAMZA should be withheld prior to surgery and discontinued if a patient develops wound healing complications.
Eli Lilly and Company Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Revised Earnings Guidance for 2015
Apr 23 15
Eli Lilly and Company reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $4,644.7 million against $4,683.1 million a year ago. The change in revenue included a 6% decline due to the unfavorable impact of foreign exchange rates, largely offset by increases of 3% due to higher prices and 3% due to increased volume. The 3% increase in worldwide volume was primarily due to the inclusion of revenue from Novartis Animal Health, U.S. wholesaler buying patterns, and increased volumes for several other products including Cyramza and Humalog®. Operating income was $525.2 million against $834.8 million a year ago. Income before income taxes was $617.9 million against $890.8 million a year ago. Net income was $529.5 million or $0.50 per diluted share against $727.9 million or $0.68 per diluted share a year ago. The declines in net income and earnings per share were driven by lower operating income, partially offset by a lower effective tax rate in 2015 and increased other income. The decline in operating income primarily driven by higher acquired in-process research and development charges and asset impairment, restructuring, and other special charges. Adjusted net income was $923.7 million or $0.87 per diluted share against $797.7 million or $0.74 per diluted share a year ago. The increases were driven by higher operating income and other income, partially offset by a higher effective tax rate. Earnings per share benefited slightly from a lower number of shares outstanding in the first quarter of 2015 compared with the first quarter of 2014. Revenue - non-GAAP was $4,644.7 million against $4,934.9 million a year ago. The revenue decline was driven by the unfavorable impact of foreign exchange rates and lower demand for Cymbalta and Evista following U.S. patent expirations, partially offset by higher prices and wholesaler buying patterns, as well as increased volumes for several other products including Cyramza and Humalog.
The company revised earnings guidance for 2015. For the year, the company now expects revenue of $19.5 billion to $20.0 billion against $19.5 billion to $20.0 billion expected earlier. Earnings per share are now expected to be in the range of $2.21 to $2.31 against $2.40 to $2.50 expected earlier on a reported basis. Non-GAAP earnings per share are still expected to be in the range of $3.10 to $3.20 against $3.10 to $3.20 expected earlier. Capital expenditures are still expected to be approx. $1.3 billion. The company expects tax rate of approx. 16.5% compared to approx. 18.5% expected earlier. The company expects tax rate (non GAAP) of approx. 21.5% compared to approx. 21.5% expected earlier.
Eli Lilly and Company Announces Audited Consolidated Cash Flow Results for Year Ended December 31, 2014
Apr 7 15
Eli Lilly and Company announced audited consolidated cash flow results for year ended December 31, 2014. For the year, the company reported net cash provided by operating activities was $4,367.1 million against $5,735.0 million a year ago. Purchases of property and equipment were $1,162.6 million against $1,012.1 million a year ago.